Rheumatic Disease Clinics of North America This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Role of Lipoprotein Levels and Function in Atherosclerosis Associated with Autoimmune Rheumatic Diseases
Immune and inflammatory mediators in autoimmune rheumatic diseases induce modification in the activity of enzymes pivotal for lipid metabolism and promote a proatherogenic serum lipid profile. However, disturbances in low- and high-density lipoprotein composition and increased lipid oxidation also occur. Therefore, lipoprotein dysfunction causes intracellular cholesterol accumulation in macrophages, smooth muscle cells, and platelets. Overall, both plaque progression and acute cardiovascular events are promoted. Single rheumatic diseases may present a particular pattern of lipid disturbances so that standard methods to eva...
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: Nicoletta Ronda, Francesca Zimetti, Maria Pia Adorni, Marcella Palumbo, George A. Karpouzas, Franco Bernini Source Type: research

Venous Thromboembolism in the Inflammatory Rheumatic Diseases
Venous thromboembolism (VTE), which includes deep venous thrombosis and pulmonary embolism, is a cardiovascular event whose risk is increased in most inflammatory rheumatic diseases (IRDs). Mechanisms that increase VTE risk include antiphospholipid antibodies (APLs), particularly anticardiolipin antibodies, anti-beta2glycoprotein I antibodies and lupus anticoagulant present together, and inflammation-mediated endothelial injury. Patients with IRDs should receive long-term anticoagulation drugs when the risk of VTE recurrence is high. In the light of recent warnings from regulatory agencies regarding heightened VTE risk wit...
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: Durga Prasanna Misra, Sakir Ahmed, Mohit Goyal, Aman Sharma, Vikas Agarwal Source Type: research

Myocardial Involvement in Systemic Autoimmune Rheumatic Diseases
Systemic autoimmune rheumatic diseases (SARDs) are defined by the potential to affect multiple organ systems, and cardiac involvement is a prevalent but often overlooked sequela. Myocardial involvement in SARDs is medicated by macrovascular disease, microvascular dysfunction, and myocarditis. Systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, eosinophilic granulomatosis with polyangiitis, and sarcoidosis are associated with the greatest risk of myocardial damage and heart failure, though myocardial involvement is also seen in other SARDs or their treatments. Management of myocardial involvement should ...
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: Alexia A. Zagouras, W.H. Wilson Tang Source Type: research

Heart Failure in Rheumatic Disease
There is a significant increase in risk of heart failure in several rheumatic diseases. Common cardiovascular risk factors and inflammatory processes, present in both rheumatic diseases and heart failure, are contributing to this increase. The opportunities for using immune-based strategies to fight development of heart failure in rheumatic diseases are evolving. The diversity of inflammation calls for a tailored characterization of inflammation, enabling differentiation of inflammation and subsequent introduction of precision medicine using target-specific strategies and immunomodulatory therapy. As the field of rheuma-ca...
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: Brian Bridal L øgstrup Source Type: research

Cardiovascular Disease in Large Vessel Vasculitis
Takayasu ’s arteritis (TAK) and giant cell arteritis (GCA) are the 2 most common primary large vessel vasculitides (LVV). They share common vascular targets, clinical presentations, and histopathology, but target a strikingly different patient demographic. While GCA predominantly affects elderly people of northern European ancestry, TAK preferentially targets young women of Asian heritage. Cardiovascular diseases (CVD), including ischemic heart disease, cerebrovascular disease, aortic disease, and thromboses, are significantly increased in LVV. In this review, we will compare and contrast the issue o f CVD in patients wi...
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: Alison H. Clifford Source Type: research

Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis
Systemic auto-immune inflammatory arthritides are associated with increased cardiovascular (CV) risk compared to those without these conditions, and is a leading cause of morbidity and mortality. Newer biologic drug modifying antirheumatoid drugs (bDMARD) and small molecules have transformed treatment paradigms enabling tighter control of disease activity and in some cases, remission. There is evidence to suggest that the majority of bDMARDs may also reduce cardiovascular risk, although prospective interventional data remain sparse. Additionally, recent results raise concern for treatments targeting specific pathways that ...
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: Brittany Weber, Katherine P. Liao Source Type: research

Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most prescribed pharmacologic therapies worldwide due to their therapeutic analgesic efficacy and relative tolerability. In the past several decades, various cardiovascular (CV) adverse events have emerged regarding both traditional NSAIDs (tNSAIDs) and cyclo-oxygenase 2 (COX-2) selective (coxibs). This review will provide an updated report on the CV risk profile of NSAIDs, focusing on several of the larger clinical trials, meta-analyses, and registry studies. We aim to provide rheumatologists with a framework for NSAID use in the context of rheumatologic chronic ...
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: Deeba Minhas, Anjali Nidhaan, M. Elaine Husni Source Type: research

Cardiovascular Comorbidities in Inflammatory Rheumatic Diseases
Patients with inflammatory rheumatic diseases experience higher cardiovascular morbidity and mortality compared with age- and gender-matched individuals in the general population. Those include atherosclerotic, ischemic complications as well as nonatherosclerotic events, such as venous thromboembolism, myocardial involvement, and heart failure. Disease flares and high cumulative inflammatory burden are characteristic of the systemic autoimmune diseases and constitute major, independent contributors to cardiovascular comorbidity. (Source: Rheumatic Disease Clinics of North America)
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: George A. Karpouzas, M. Elaine Husni Tags: Preface Source Type: research

Cardiovascular Comorbidities in Inflammatory Rheumatic Diseases
Drs Karpouzas and Husni have assembled a series of articles that address one of the most important issues facing our management of systemic rheumatic disease patients in the modern era, the prevention and (hopefully) successful identification and avoidance of cardiovascular morbidity and mortality. In the 1960s and 1970s, patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) actually died directly from the heart and vascular complications of their disease. This has been reversed. (Source: Rheumatic Disease Clinics of North America)
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: Michael H. Weisman Tags: Foreword Source Type: research

Cardiovascular Complications of Chronic Rheumatic Diseases
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (Source: Rheumatic Disease Clinics of North America)
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Authors: George A. Karpouzas, M. Elaine Husni Source Type: research

Copyright
ELSEVIER (Source: Rheumatic Disease Clinics of North America)
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Source Type: research

Contributors
MICHAEL H. WEISMAN, MD (Source: Rheumatic Disease Clinics of North America)
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Source Type: research

Contents
Michael H. Weisman (Source: Rheumatic Disease Clinics of North America)
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Source Type: research

Forthcoming Issues
Scleroderma: Best Approaches to Patient Care (Source: Rheumatic Disease Clinics of North America)
Source: Rheumatic Disease Clinics of North America - November 22, 2022 Category: Rheumatology Source Type: research

Inhalant and Additional Mucosal-Related Environmental Risks for Rheumatoid Arthritis
Rheumatoid arthritis (RA) occurs as the result of a complex interplay of environmental factors in a genetically susceptible individual. There is considerable evidence that the lungs may serve as an initial site of tolerance loss in the generation of RA-related autoimmunity, and several environmental inhalant exposures and lung diseases have been associated with RA risk. There is additional evidence that immune and microbial dysregulation of other mucosal sites, including the oral and gastrointestinal mucosa, may contribute to the development of RA. Epidemiologic evidence linking mucosal exposures to various environmental i...
Source: Rheumatic Disease Clinics of North America - November 1, 2022 Category: Rheumatology Authors: Brent A. Luedders, Ted R. Mikuls, Geoffrey M. Thiele, Jill A. Poole, Bryant R. England Source Type: research